About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Diabetes Technology & Therapeutics

Editor-in-Chief: Satish K. Garg, MD

ISSN: 1520-9156 • Published Monthly • Online ISSN: 1557-8593

Current Volume: 16

Latest Impact Factor* is 2.293

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    STATEMENT OF PURPOSE AND POLICY


    Diabetes Technology & Therapeutics will accept original papers and reviews about the use of technology and products to treat, diagnose, and prevent diabetes. Manuscripts submitted to Diabetes Technology & Therapeutics must not contain material that has been reported elsewhere (except in the form of an abstract published for a scientific meeting) or be under consideration for publication elsewhere. Prior abstracts should be described in a footnote to the title. 
     

    Diabetes Technology & Therapeutics is a rapid publication journal.  Articles are published online ahead of print in 3-4 weeks.


    PLEASE READ ALL THE INSTRUCTIONS TO AUTHORS BEFORE SUBMITTING.

    All manuscripts must be submitted online at http://mc.manuscriptcentral.com/diabetestechnology
     

    PREPARATION OF MANUSCRIPT 

    Prepare manuscripts double-spaced.  Leave ample margins on both sides, top and bottom.

    Word limits are as follows:

    • Original paper:  5000 words, each table or figure accounts for 400 words.
    • Invited paper or review articles:   6000 words with no more than 2-3 tables or figures.
    • Brief reports:  1500-2000 words, plus 1 table and 1 figure.
    • Invited editorials: 1,500 words, with no more than 1 table or figure, and up to 30 references.

    A title page should be part of your main text file and should  include all authors’ names and affiliations, the funding source (if appropriate), and a running title of up to 45 characters.  Please indicate the name, address, phone number, fax number, and e-mail address of the author to whom reprint requests should be addressed.


    Include a minimum of five keywords on the title page to facilitate the review process.
     

    The abstract should be no more than 250 words. Abstracts of original papers should contain four paragraphs labeled as: Background, Methods, Results, and Conclusions. Abstracts of reviews should contain a single unlabeled paragraph.

    Disclosure Statement

    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.”

    In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision.

    Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance.

    If no conflicts exist, the authors must state “No competing financial interests exist.

    TABLES AND ILLUSTRATIONS

    Tables should be prepared in Word and be supplied in a separate file from the text.  Use Arabic numerals to number tables. Each table must stand alone, i.e., contain all necessary information in the caption, and the table itself must be understood independently of the text. Details of experimental conditions should be included in the table footnotes. Information that appears in the text should not be repeated in the table, and tables should not contain data that can be given in the text in one or two sentences.  Each supplied table must have a title.

    Please submit artwork according to the following guidelines:
     

    Please follow these guidelines for submitting artwork:

    • Do NOT embed art files into a Word or PDF document.
    • Line illustrations should be submitted at  900 dpi.
    • Halftones and color should be submitted at a minimum of 300 dpi.
    • Save as either TIFF or EPS files.
    • Color art must be saved as CYMK - not RGB.
    • Black and White art must be submitted as grayscale – not RGB.
    • Do NOT submit PowerPoint, PDF, Bitmap or Excel files.

    Please name your artwork files with the submitting authors name i.e. SmithFig1.tif, SmithTable2.tif etc.  Authors who do not follow these guidelines may have their submission returned to them without being reviewed.

    ADDITIONAL INFORMATION ABOUT ART FILES

    Converting Word or Excel files:  Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:
     

    • All files should be scanned at 100% size.
    • 300 dpi
    • Final color mode: cmyk
    • save file as: .tif or .eps
     
    If you need directions on how to convert a Power Point slide to acceptable format go to http://www.liebertpub.com/MEDIA/pdf/ppconvert.pdf  

    AUTHOR DISCLOSURE

    All authors are expected to disclose any institutional or commercial affiliations that might pose a conflict of interest regarding the publication of a manuscript. Institutional affiliations, as indicated on the title page, should include all corporate affiliations and any funding sources that support the work. Other types of affiliation, including consultantships, honoraria, stock ownership, equity interests, arrangements regarding patents, or other vested interests should be disclosed in the Acknowledgments section.

    REFERENCES

    List references in consecutive numerical order (not alphabetically). All subsequent reference citations should be to the original number.  Cite all references in the text or tables. Unpublished data and personal communications should not be listed as references.  Abbreviations of journal titles should follow MEDLINE.


    References to journal papers should include: (1) author(s) (list the first three authors, followed by et al. if applicable), (2) title, (3) journal name (as abbreviated in MEDLINE), (4) year, (5) volume number, and 6) inclusive page numbers, in that order.
     

    References to books should include: (1) author(s), (2) chapter title (if any), (3) editor (if any), (4) title of book, (5) city of publication, (6) publisher, and (7) year. Volume and edition numbers, specific pages, and name of translator should be included when appropriate. The author is responsible for the accuracy and completeness of the references and for their correct text citation.

    AUTHORSHIP

    It is the submitting author’s responsibility to ensure the accuracy and inclusion of all contributing authors’ names and affiliations upon original submission of the paper. Once a paper is accepted for publication, changes in authorship while the paper is in production – including page proofs – are NOT permitted. Changes in authorship after publication are strictly prohibited.

    PATIENT RELEASE INFORMATION

    If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients.  The submitting author should provide written confirmation of this critical information.  Acceptable forms of consent statements are emails or letters.  The Journal does not provide a generic patient release form.

    The written consent must contain specific information about the patient's name, age, and if pertinent, conservatorship -- as well as stated permission -- granting the Journal the rights to publish the photograph within its pages (which includes the name of the Journal and article title).  

    PERMISSIONS

    The author must obtain permission to reproduce figures, tables and text from previously published material. Written permission must be obtained from the original copyright holder (generally the publisher, not the author or editor) of the journal or book concerned. An appropriate credit line should be included in the figure or legend or table footnote, and full publication information should be included in the reference list. Written permission must be obtained from the author of any unpublished material and should accompany the manuscript.

    REPRINTS

    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    PUBLISHER

    The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: 914-740-2100; fax: 914-740-2101. E-mail: info@liebertpub.com Online: www.liebertpub.com 

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Metabolic Syndrome
    and Related Disorders

    Metabolic Syndrome
    and Related Disorders

    The only peer-reviewed journal focusing solely on the pathophysiology, recognition, and treatment of this major health condition.

    Childhood Obesity

    Childhood Obesity

    Explores effective, actionable strategies for weight management and obesity prevention in children and adolescents, with in-depth coverage on education, policy, health disparities and cultural sensitivities, and more.

    Population Health Management

    Population Health Management

    Comprehensive, authoritative strategies for improving the systems and policies that affect health care quality, access, and outcomes, ultimately improving the health of an entire population.

Browse All Publications »


ATTD launches brand new Diabetes Technology Connection newsletter!